T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer


Phase(s)
2

Drug Pill Drug
Cyclophosphamide, Fludarabine, Aldesleukin

Biological treatment cell Biological
Anti-NY ESO-1 mTCR PBL
Trial Summary

Background:
The NCI Surgery Branch has developed an experimental therapy for treating patients with cancer that involves taking white blood cells from the patient, growing them in the laboratory in large numbers, genetically modifying them, and then giving the cells back to the patient. In a previous study the NCI Surgery Branch used the anti-ESO-1 gene and a type of virus (retrovirus) to make these tumor fighting cells (anti-ESO-1 cells). About half of the patients who received this treatment experienced shrinking of their tumors. In this study, we are using a slightly different method of producing the anti-ESO-1 cells which we hope will be better in making the tumors shrink.

Objectives:
The purpose of this study is to see if these tumor fighting cells (genetically modified cells) that express the receptor for the ESO-1 molecule on their surface can cause tumors to shrink and to see if this treatment is safe.

Eligibility:
Patients 15 years old and older with cancer that has the ESO-1 molecule on their tumors.

Ages: 15 Years to 70 Years
Condition: Melanoma, Meningioma, Breast Cancer, Non-Small Cell Lung Cancer, Hepatocellular Cancer
Status
Recruiting
Location(s)
National Institutes of Health (NIH) Clinical Center, Bethesda, MD

Sponsor/Collaborators:
National Cancer Institute (NCI), National Institutes of Health (NIH) Clinical Center (CC)
Contact
Margaret Shovlin, RN
866-820-4505